Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

The Impact of Ischemic Time on the Predictive Value of High-Sensitivity C-Reactive Protein in ST-Segment Elevation Myocardial Infarction Patients Treated by Primary Percutaneous Coronary Intervention

  • Kim, Kyung Hwan (Division of Cardiology, Department of Internal Medicine, Gwangju Veterans Hospital) ;
  • Kim, Wan (Division of Cardiology, Department of Internal Medicine, Gwangju Veterans Hospital) ;
  • Kang, Won Yu (Division of Cardiology, Department of Internal Medicine, Gwangju Veterans Hospital) ;
  • Hwang, Sun Ho (Division of Cardiology, Department of Internal Medicine, Gwangju Veterans Hospital) ;
  • Cho, Sang Cheol (Division of Cardiology, Department of Internal Medicine, Gwangju Veterans Hospital) ;
  • Kim, Weon (Department of Cardiovascular Medicine, Kyung Hee University College of Medicine) ;
  • Jeong, Myung Ho (Department of Cardiovascular Medicine, Chonnam National College of Medicine) ;
  • Korean Working Group in Myocardial Infarction Investigators, (Korean Working Group in Myocardial Infarction Investigating Hospitals)
  • Published : 2013.10.31
⟨ Previous Next ⟩

Abstract

Background and Objectives: The high-sensitivity C-reactive protein (hs-CRP), a marker of inflammation, has been known to be elevated in patients with coronary artery disease. However, there is controversy about the predictive value of hs-CRP after acute myocardial infarction (MI). Therefore, we evaluated the impact of ischemic time on the predictive value of hs-CRP in ST-segment elevation myocardial infarction (STEMI) patients who were treated by primary percutaneous coronary intervention (PCI). Subjects and Methods: We enrolled 5123 STEMI patients treated by primary PCI from the Korean Working Group in Myocardial Infarction and divided enrolled patients into four groups by symptom-to-balloon time (SBT) and level of hs-CRP (Group I: SBT <6 hours and hs-CRP <3 mg/L, Group II: SBT <6 hours and hs-CRP ${\geq}3$ mg/L, Group III: SBT ${\geq}6$ hours and hs-CRP <3 mg/L, and Group IV: SBT ${\geq}6$ hours and hs-CRP ${\geq}3$ mg/L). To evaluate the impact of ischemic time on the predictive value of hs-CRP in STEMI patients, we compared the cumulative cardiac event-free survival rate between these four groups. Results: The sum of the cumulative incidence of all-cause mortality and recurrence of MI was higher in Group IV than in the other groups. However, there was no significant difference among Group I, Group II, and Group III. The Cox-regression analyses showed that an elevated level of hs-CRP (${\geq}3$ mg/L) was an independent predictor of long-term cardiovascular outcomes only among late-presenting STEMI patients (p=0.017, hazard ratio=2.462). Conclusion: For STEMI patients with a long ischemic time (${\geq}6$ hours), an elevated level of hs-CRP is a poor prognostic factor of long-term cardiovascular outcomes.

Keywords

References

  1. Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001;47:418-25.
  2. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511. https://doi.org/10.1161/01.CIR.0000052939.59093.45
  3. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-908. https://doi.org/10.1056/NEJMoa0707402
  4. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL; Intermountain Heart Collaboration Study Group. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002;39:632-7. https://doi.org/10.1016/S0735-1097(01)01804-6
  5. Bogaty P, Poirier P, Simard S, Boyer L, Solymoss S, Dagenais GR. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 2001;103:3062-8. https://doi.org/10.1161/01.CIR.103.25.3062
  6. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabili ties Angina Pectoris Study Group. Lancet 1997;349:462-6. https://doi.org/10.1016/S0140-6736(96)07591-5
  7. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 2000;140:324-8. https://doi.org/10.1067/mhj.2000.108244
  8. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-41. https://doi.org/10.1056/NEJM199503093321003
  9. Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007;115:1528-36. https://doi.org/10.1161/CIRCULATIONAHA.106.649939
  10. Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004;44:335-9. https://doi.org/10.1016/j.jacc.2004.04.033
  11. Nikfardjam M, Mullner M, Schreiber W, et al. The association between C-reactive protein on admission and mortality in patients with acute myocardial infarction. J Intern Med 2000;247:341-5. https://doi.org/10.1046/j.1365-2796.2000.00670.x
  12. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010;122:2748-64. https://doi.org/10.1161/CIR.0b013e3182051bab
  13. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990;65:168-72. https://doi.org/10.1016/0002-9149(90)90079-G
  14. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 2000;140:324-8. https://doi.org/10.1067/mhj.2000.108244
  15. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of Creactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24. https://doi.org/10.1056/NEJM199408183310701
  16. Liuzzo G, Biasucci LM, Gallimore JR, et al. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol 1999;34:1696-703. https://doi.org/10.1016/S0735-1097(99)00432-5
  17. Hong YJ, Jeong MH, Choi YH, et al. Relation between high-sensitivity C-reactive protein and coronary plaque components in patients with acute coronary syndrome: virtual histology-intravascular ultrasound analysis. Korean Circ J 2011;41:440-6. https://doi.org/10.4070/kcj.2011.41.8.440
  18. Lagrand WK, Niessen HW, Wolbink GJ, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997;95:97-103. https://doi.org/10.1161/01.CIR.95.1.97
  19. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999;190:1733-40. https://doi.org/10.1084/jem.190.12.1733
  20. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-21. https://doi.org/10.1038/nature04672
  21. Ahmed K, Jeong MH, Chakraborty R, et al. Prognostic impact of baseline high-sensitivity C-reactive protein in patients with acute myocardial infarction undergoing percutaneous coronary intervention based on body mass index. Korean Circ J 2012;42:164-72. https://doi.org/10.4070/kcj.2012.42.3.164
  22. Vrsalovic M, Pintaric H, Babic Z, et al. Impact of admission anemia, Creactive protein and mean platelet volume on short term mortality in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Clin Biochem 2012;45:1506-9. https://doi.org/10.1016/j.clinbiochem.2012.05.026
  23. Mouridsen MR, Intzilakis T, Binici Z, Nielsen OW, Sajadieh A. Prognostic value of high sensitive C-reactive protein in subjects with silent myocardial ischemia. J Electrocardiol 2012;45:260-4. https://doi.org/10.1016/j.jelectrocard.2011.11.004
  24. Raposeiras-Roubin S, Barreiro Pardal C, Rodino Janeiro B, Abu-Assi E, Garcia-Acuna JM, Gonzalez-Juanatey JR. High-sensitivity C-reactive protein is a predictor of in-hospital cardiac events in acute myocardial infarction independently of GRACE risk score. Angiology 2012;63:30-4. https://doi.org/10.1177/0003319711406502
  25. Schoos MM, Kelbæk H, Kofoed KF, et al. Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. Am J Cardiol 2011;107:1597-603. https://doi.org/10.1016/j.amjcard.2011.01.042

Cited by

  1. Independent and joint effects of high-sensitivity c-reactive protein and hypoalbuminemia on long-term all-cause mortality among coronary artery disease: a prospective and multicenter cohort study vol.21, pp.1, 2013, https://doi.org/10.1186/s12872-021-02431-6